CN112218949B - 多瘤病毒复制的抑制 - Google Patents

多瘤病毒复制的抑制 Download PDF

Info

Publication number
CN112218949B
CN112218949B CN201980029743.2A CN201980029743A CN112218949B CN 112218949 B CN112218949 B CN 112218949B CN 201980029743 A CN201980029743 A CN 201980029743A CN 112218949 B CN112218949 B CN 112218949B
Authority
CN
China
Prior art keywords
seq
oligonucleotide
aon
mrna
nucleobases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980029743.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112218949A (zh
Inventor
埃里克·彼得·范德维尔
安东·扬·范宗内维德
朱瑞恩·普林斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61563209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112218949(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Priority to CN202411905029.4A priority Critical patent/CN119823988A/zh
Publication of CN112218949A publication Critical patent/CN112218949A/zh
Application granted granted Critical
Publication of CN112218949B publication Critical patent/CN112218949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980029743.2A 2018-03-02 2019-03-01 多瘤病毒复制的抑制 Active CN112218949B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411905029.4A CN119823988A (zh) 2018-03-02 2019-03-01 多瘤病毒复制的抑制

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18159797.2 2018-03-02
EP18159797 2018-03-02
PCT/NL2019/050131 WO2019168402A1 (en) 2018-03-02 2019-03-01 Inhibition of polyomavirus replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411905029.4A Division CN119823988A (zh) 2018-03-02 2019-03-01 多瘤病毒复制的抑制

Publications (2)

Publication Number Publication Date
CN112218949A CN112218949A (zh) 2021-01-12
CN112218949B true CN112218949B (zh) 2025-02-11

Family

ID=61563209

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980029743.2A Active CN112218949B (zh) 2018-03-02 2019-03-01 多瘤病毒复制的抑制
CN202411905029.4A Pending CN119823988A (zh) 2018-03-02 2019-03-01 多瘤病毒复制的抑制

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411905029.4A Pending CN119823988A (zh) 2018-03-02 2019-03-01 多瘤病毒复制的抑制

Country Status (7)

Country Link
US (2) US11661602B2 (enExample)
EP (1) EP3759221A1 (enExample)
JP (2) JP7532257B2 (enExample)
CN (2) CN112218949B (enExample)
BR (1) BR112020017949A2 (enExample)
CA (1) CA3092817A1 (enExample)
WO (1) WO2019168402A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168402A1 (en) * 2018-03-02 2019-09-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Inhibition of polyomavirus replication
IL316802A (en) * 2022-05-06 2025-01-01 Academisch Ziekenhuis Leiden Oligonucleotide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511995A (zh) * 2005-08-02 2009-08-19 焦点诊断公司 检测bk病毒的方法和组合物
CN102363818A (zh) * 2011-06-28 2012-02-29 同昕生物技术（北京）有限公司 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2007536937A (ja) * 2004-05-12 2007-12-20 カメル・カリーリ 霊長類ポリオーマウイルス遺伝子のｓｉＲＮＡ干渉用組成物および方法
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2008077511A1 (en) * 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
US20110118340A1 (en) * 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
US20090246754A1 (en) * 2008-02-19 2009-10-01 Intelligent Mdx Optimized probes and primers and methods of using same for the detection and quantitation of bk virus
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
WO2013119979A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Methods and compositions for modulating factor vii expression
CN103276107B (zh) * 2013-05-13 2014-11-19 中国医学科学院病原生物学研究所 一种高灵敏度检测和鉴定人多瘤病毒的方法
EP3047023B1 (en) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting jc virus (jcv)
AU2016366229A1 (en) * 2015-12-09 2018-05-17 Excision Biotherapeutics, Inc. Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
ES2903394T3 (es) * 2015-12-14 2022-04-01 Cold Spring Harbor Laboratory Composiciones para el tratamiento de la retinitis pigmentosa 13
US11096956B2 (en) * 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2019168402A1 (en) * 2018-03-02 2019-09-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Inhibition of polyomavirus replication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511995A (zh) * 2005-08-02 2009-08-19 焦点诊断公司 检测bk病毒的方法和组合物
CN102363818A (zh) * 2011-06-28 2012-02-29 同昕生物技术（北京）有限公司 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒

Also Published As

Publication number Publication date
CN112218949A (zh) 2021-01-12
WO2019168402A1 (en) 2019-09-06
CN119823988A (zh) 2025-04-15
JP2024156786A (ja) 2024-11-06
US12480122B2 (en) 2025-11-25
US20210010004A1 (en) 2021-01-14
CA3092817A1 (en) 2019-09-06
EP3759221A1 (en) 2021-01-06
JP7532257B2 (ja) 2024-08-13
BR112020017949A2 (pt) 2020-12-22
US11661602B2 (en) 2023-05-30
US20230212580A1 (en) 2023-07-06
JP2021524730A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
Xu et al. Adenovirus virus-associated RNAII-derived small RNAs are efficiently incorporated into the rna-induced silencing complex and associate with polyribosomes
Taulli et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation
TWI859216B (zh) 工程化生產細胞株以及製造及使用該細胞株之方法
Gao et al. 6mer seed toxicity in tumor suppressive microRNAs
JP2024156786A (ja) ポリオーマウイルス複製の阻害
WO2009023525A2 (en) Methods of modulating mesenchymal stem cell differentiation
Gasperini et al. Piwil2 (Mili) sustains neurogenesis and prevents cellular senescence in the postnatal hippocampus
WO2017156591A1 (en) Osteoarthritis mirnas
CN106399313B (zh) 一种抗PRRSV的microRNA样病毒小RNA序列及其用途和检测方法
CN116194583A (zh) 治疗脂肪肝病的方法
KR20260051070A (ko) 기능적 핵산
KR20210066758A (ko) 8-옥소구아닌을 포함하는 rna 간섭 유도 핵산, 8-옥소구아닌을 포함하는 마이크로rna와 결합하는 변형 핵산 및 이들의 이용
HK40118055A (zh) 多瘤病毒复制的抑制
Gasperini et al. The piRNA pathway sustains adult neurogenesis by reducing protein synthesis and cellular senescence
CN116356431A (zh) 基于牛全基因组CRISPR-Cas9敲除文库、敲除细胞库及筛选目标基因的方法
WO2015148624A1 (en) Blocking hepatitis c virus infection associated liver tumor development with hcv-specific antisense rna
US20250136942A1 (en) Methods to accelerate stem cell differentiation to cardiomyocytes
CN115052590B (en) RNA interference-inducing nucleic acids comprising 8-oxoguanine, modified nucleic acids that bind to microRNAs comprising 8-oxoguanine, and uses thereof
Lyu et al. CRISPR/Cas9-based knockout of miR-487b-3p accelerates the cell proliferation of primary goat myoblast by relieving its inhibition of IRS1
CN111647658B (zh) Linc00963相关致癌轴在前列腺癌远处转移的早期诊断和治疗中的应用
Zhang et al. RNAi Degrades the SARS-CoV-2 Spike Protein RNA for Developing Drugs to Treat COVID-19
Taylor Regulation of Diabetic Cardiomyopathy Through Mitochondrial Import of Long Non-Coding RNAs
Niazi et al. MicroRNA Nobel Prize: A Timely Recognition, and a High Anticipation—A Detailed Analysis to Assist
Wang et al. Liu,., anssen
Hackbart et al. S RNA Intergenic Deletions Drive Viral Interference during Arenavirus Infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390521